Delivery Order HHSN261201500041I-HHSN26100002
Award Date
9/24/15
Potential Completion Date
1/25/18
Potential Value
$509K
Federal Agency
National Cancer Institute
Awardee
Sri International
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $712,240 firm fixed-price delivery order awarded to SRI International, a non-profit research and development institute, by the National Cancer Institute (NCI). The contract is part of the NCI's Preclinical Prevention Cancer Program and supports the "Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer" project. This R&D effort focuses on basic biomedical research towards developing a preventive vaccine for ovarian cancer. The...
This is a federal contract award from the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract, worth $21,593,775.02, is for "PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND OTHER THERAPEUTIC AGENTS" and was awarded on December 15, 2004 with a completion date of December 14, 2012. The contract type is Definitive Contract with a Cost Plus Fixed Fee pricing...
This is a $7,910,623.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (part of the U.S. Department of Health and Human Services) to SRI International, a non-profit research and development institute. The contract is for analysis of anti-cancer chemicals and pharmaceutical formulations. It does not have a small business set-aside designation. SRI International frequently serves as a prime contractor and subcontractor on research and development contracts and grants with...
This is a $67,787,765.29 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to SRI International, a non-profit research and development institute, for preclinical toxicology and pharmacology of drugs. The contract supports biomedical research and drug development services for the NCI. SRI International has multiple indefinite delivery vehicles (IDVs) with federal agencies like the Department of Defense, NASA, and the National Institutes of Health that enable efficient...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency, to SRI International, a non-profit research and development institute. The $35,252.94 cost-plus-fixed-fee contract is for the release analysis (appearance, PMR, IR, HPLC (assay; impurity), moisture, residual solvents, ROI and heavy metals) of 2 bulk drug lots of NSC 706744. The work will be performed from February 24, 2020 to September 30, 2020. This requirement is part of the NCI's "Analysis...
This federal contract award is for an "OTHER FUNCTIONS - CONTRACT ORIENTATION MEETING WITH NCI, OFFICE OF ACQUISITIONS" valued at $4,144.00. The award was made by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services, to the prime contractor Sri International, a non-profit research and development institute. The contract is a Delivery Order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers contract vehicle. Sri...
This is a federal contract awarded by the National Cancer Institute, a component of the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract is for the synthesis of non-GMP (non-Good Manufacturing Practice) small molecules, with a total ceiling value of $5,499,854.59. The contract type is Cost Plus Fixed Fee, and the ultimate completion date is June 30, 2012. SRI International has a history of supporting federal agencies...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency, to SRI International, a non-profit research and development institute. The $26,166.42 contract is for the analysis of anti-cancer chemicals and pharmaceutical formulations, including tests for appearance, NMR, IR, HPLC, residual solvents, moisture, residue on ignition, and heavy metals for a specific chemical compound, NSC 706744. This contract is part of a larger $26.2 million...
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The objective of the $25,685.62 contract is to provide services, personnel, equipment, and facilities to perform analysis of bulk drug substances and formulated drug products under current good manufacturing practice (cGMP) conditions. The contract has a period...